Alnylam Seeking Lumasiran Approvals Soon, But Has Two Rivals On Its Heels

 
• By Mandy Jackson

Phase III results support early 2020 filings for what could be the RNAi specialist’s third commercial product, but two competing drugs for primary hyperoxaluria from Dicerna and OxThera aren’t far behind. 

Kidney
Primary hyperoxaluria type 1 causes kidney stones and renal disease. • Source: Shutterstock

More from Clinical Trials

More from R&D